News & Updates

Show Multimedia Only

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

20 Aug 2025 by

Patients with postbariatric hypoglycaemia (PBH) may benefit from using mizagliflozin, which contributes to significant reductions in hypoglycaemic events, reports a study presented at ENDO 2025.

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

20 Aug 2025

Setmelanotide lowers BMI in patients with hypothalamic obesity

20 Aug 2025 by

Treatment with setmelanotide results in significant BMI reductions in individuals with acquired hypothalamic obesity compared with placebo, with an acceptable safety profile, as shown by the results of a phase III study presented at ENDO 2025.

Setmelanotide lowers BMI in patients with hypothalamic obesity

20 Aug 2025

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

Monotherapy with rivaroxaban in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) appears to protect against the risks of major adverse cardiovascular event (MACE) and major bleeding, with the benefit observed across the broad range of age, according to a post hoc analysis of the open-label AFIRE* trial.

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

20 Aug 2025

Vape or e-cigarette is a rather recent arrival in the nicotine delivery route. As such, little is known about the long-term effects of vaping. However, developments in recent years have brought vaping to the limelight as it is becoming increasingly obvious that the vape industry is targeting youth. Initially unintentional, but increasingly deliberate as it became obvious that youth were a valuable source of current and future income.

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

20 Aug 2025

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

GLP-1 drugs can raise testosterone levels in men

19 Aug 2025 by

The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.

GLP-1 drugs can raise testosterone levels in men

19 Aug 2025

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

19 Aug 2025 by

The use of lenacapavir is highly efficacious in pregnant and lactating people (PLP), with zero participants acquiring HIV, as shown by the results of the PURPOSE 1 study.

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

19 Aug 2025

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025 by

Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

Setmelanotide lowers BMI in patients with hypothalamic obesity

Setmelanotide lowers BMI in patients with hypothalamic obesity

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

GLP-1 drugs can raise testosterone levels in men

GLP-1 drugs can raise testosterone levels in men

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Combo therapy enhances fat loss while preserving lean mass

Combo therapy enhances fat loss while preserving lean mass

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)